Boehringer Ingelheim partners with PetMedix Boehringer Ingelheim partners with PetMedix Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
collaboration criving innovation collaboration criving innovation In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Partnering pet therapeutics Partnering pet therapeutics Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Strategic-collaboration-with-EnaraBio Strategic-collaboration-with-EnaraBio Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Partnership to Develop Urea Cycle Disorders Therapy Partnership to Develop Urea Cycle Disorders Therapy Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
Building Lasting Partnerships for a Better Future Building Lasting Partnerships for a Better Future Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Partnering with Constantia Flexibles for augmented reality Partnering with Constantia Flexibles for augmented reality Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Official partner to Cat Care for Life Official partner to Cat Care for Life Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Our partners Bioveta Our partners Bioveta Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
New cancer research building: Boosting innovation in oncology New cancer research building: Boosting innovation in oncology With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Three challenges shape future antiparasitic treatment Three challenges shape future antiparasitic treatment The three key challenges that will shape the future of antiparasitic treatment
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
The digital therapeutic solution halving hospitalization rates The digital therapeutic solution halving hospitalization rates Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
“Rapid progress towards clinical candidates” “Rapid progress towards clinical candidates” Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Partnering in Central Nervous System Diseases Partnering in Central Nervous System Diseases We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Henke-Sass Wolf develop needle free device Henke-Sass Wolf develop needle free device Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
collaboration-LIBD collaboration-LIBD Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Respiratory Diseases Respiratory Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Cardiometabolic Diseases Cardiometabolic Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Making-more-health-together-2021 Making-more-health-together-2021 1,200 participants from around the world join virtual convention on November 11-12